Last Updated 16 September 2014 Owing to its large population, the treatment of breast cancer remains an active area of research with a rich and diverse product pipeline. A competitive current…
Treatment of colorectal cancer (CRC) represents a multibillion-dollar market. CRC is one of the most common forms of cancer in both men and women. Over the next ten years, the number of incident…
Gastrointestinal stromal tumors (GISTs) are rare cancers that belong to a group of cancers known as soft tissue sarcomas, which develop in supporting and connective tissues. GISTs account for…
LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer…
The era of personalized medicine is already well established in oncology. Biomarker-driven targeted therapies are among the top-selling oncology products today, and the impact of molecular…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. More than half of advanced AMD patients suffer the wet (exudative, neovascular) form of the disease,…
The strongest risk factor that drives change in the incidence of non-small-cell lung cancer (NSCLC) is the historical prevalence of smoking. The long lag between the initiation of tobacco use and…
The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in…
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung…
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…
